BioAtla, Inc. (BCAB)
After hours:
| Previous Close | 3.1600 |
| Open | 3.2300 |
| Bid | 3.1900 x 100 |
| Ask | 3.2700 x 200 |
| Day's Range | 3.1000 - 3.3000 |
| 52 Week Range | 1.2400 - 4.0680 |
| Volume | |
| Avg. Volume | 624,101 |
| Market Cap | 156.345M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5800 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
GlobeNewswireBioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024. Presentation Details: T
Simply Wall St.We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insider MonkeyBioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB) Q4 2023 Earnings Call Transcript March 26, 2024 BioAtla, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the BioAtla Fourth Quarter and Full Year 2023 Earnings Call. At this time, all participants […]
